{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:57:02Z","timestamp":1775152622173,"version":"3.50.1"},"reference-count":16,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2026,3,13]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study was to investigate acute opioid dose changes among patients started on a continuous subcutaneous infusion (CSCI) containing alfentanil or morphine within a specialist palliative care inpatient unit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective case note review of all inpatients admitted to a specialist palliative care unit during a 12-month period. The data collected included previous opioid analgesic, previous opioid regular dosage, opioid in CSCI, opioid in CSCI dosage (day 0 to day 7), duration of CSCI and reason for ending CSCI (if applicable).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 7\u2009days, 64% of patients receiving morphine were on a higher dose, 29% remained on the same dose, and 7% were on a lower dose. Likewise, after 7\u2009days, 73.5% of patients receiving alfentanil were on a higher dose, 20.5% remained on the same dose, and 6% were on a lower dose. A statistically significant difference between the percentage change in opioid dose at 7\u2009days between the two groups was found, that is, alfentanil greater than morphine (p=0.04724).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study review found that many patients commenced on an opioid CSCI required dose escalation over the first 7\u2009days, although dose escalation was more common and was of a greater amount in patients receiving alfentanil as compared with those receiving morphine. Given the results, it is difficult to exclude the possibility of the development of pharmacological tolerance (ie, pharmacodynamic tolerance and\/or pharmacokinetic tolerance) in some patients receiving alfentanil.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/spcare-2026-006097","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:20:20Z","timestamp":1775150420000},"page":"spcare-2026-006097","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Rapidly escalating doses of subcutaneous alfentanil (versus subcutaneous morphine) in palliative care inpatients: a case note review study"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5796-5518","authenticated-orcid":false,"given":"Kate Ji Ling","family":"Ng","sequence":"first","affiliation":[{"name":"Trinity College Dublin School of Medicine, Dublin, Leinster, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3967-0809","authenticated-orcid":false,"given":"Hoda","family":"Darwish","sequence":"additional","affiliation":[{"name":"Trinity College Dublin School of Medicine, Dublin, Leinster, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"O\u2019Boyle","sequence":"additional","affiliation":[{"name":"University College Dublin School of Medicine, Dublin, Leinster, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Scanlon","sequence":"additional","affiliation":[{"name":"University College Dublin School of Medicine, Dublin, Leinster, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4207-4799","authenticated-orcid":false,"given":"Andrew Neil","family":"Davies","sequence":"additional","affiliation":[{"name":"Trinity College Dublin School of Medicine, Dublin, Leinster, Ireland"},{"name":"University College Dublin School of Medicine, Dublin, Leinster, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"2026040210201297000_spcare-2026-006097v1.1","unstructured":"Electronic medicines compendium website. Available: https:\/\/www.medicines.org.uk\/emc [Accessed 17 Dec 2025]."},{"key":"2026040210201297000_spcare-2026-006097v1.2","doi-asserted-by":"publisher","DOI":"10.1177\/0269216311406313"},{"key":"2026040210201297000_spcare-2026-006097v1.3","unstructured":"Wilcock A , Howard P , Charlesworth S . Palliative Care Formulary. 8th edn. London: Pharmaceutical Press, 2022."},{"key":"2026040210201297000_spcare-2026-006097v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(93)90007-C"},{"key":"2026040210201297000_spcare-2026-006097v1.5","unstructured":"Hanks G , Roberts CJC , Davies AN . Principles of Drug Use in Palliative Medicine. 3rd edn. Oxford: Oxford University Press, 2004:213\u201325."},{"key":"2026040210201297000_spcare-2026-006097v1.6","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200007000-00021"},{"key":"2026040210201297000_spcare-2026-006097v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(92)90235-4"},{"key":"2026040210201297000_spcare-2026-006097v1.8","unstructured":"Our lady\u2019s hospice & care services website. Available: https:\/\/olh.ie\/wp-content\/uploads\/2022\/06\/Opioid-Conversion-Chart-2020-1.pdf [Accessed 17 Dec 2025]."},{"key":"2026040210201297000_spcare-2026-006097v1.9","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0140-6736(95)91019-0","article-title":"Opioid analgesia in uraemic patients","volume":"345","author":"Kirkham","year":"1995","journal-title":"The Lancet"},{"key":"2026040210201297000_spcare-2026-006097v1.10","doi-asserted-by":"publisher","DOI":"10.1191\/0269216304pm910oa"},{"key":"2026040210201297000_spcare-2026-006097v1.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2017-001349"},{"key":"2026040210201297000_spcare-2026-006097v1.12","article-title":"Use of Alfentanil in Palliative Care","volume":"8","author":"Ferraz Gon\u00e7alves","year":"2020","journal-title":"Pharmacy (Basel)"},{"key":"2026040210201297000_spcare-2026-006097v1.13","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1136\/bmjspcare-2022-003621","article-title":"Alfentanil conversion ratios and successful analgesia","volume":"13","author":"Taylor","year":"2024","journal-title":"BMJ Support Palliat Care"},{"key":"2026040210201297000_spcare-2026-006097v1.14","first-page":"77","article-title":"Review of alfentanil switching in a specialist palliative care service","volume":"30","author":"Ma","year":"2016","journal-title":"Palliat Med"},{"key":"2026040210201297000_spcare-2026-006097v1.15","doi-asserted-by":"crossref","unstructured":"Myles H , Featherstone H . Case report: rotation of high dose alfentanil to oxycodone via continuous subcutaneous infusion. BMJ Support Palliat Care 2022. doi:10.1136\/spcare-2022-SCPSC.99","DOI":"10.1136\/spcare-2022-SCPSC.99"},{"key":"2026040210201297000_spcare-2026-006097v1.16","first-page":"243","article-title":"Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline","volume":"33","author":"Davis","year":"2025","journal-title":"Support Care Cancer"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2026-006097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:20:22Z","timestamp":1775150422000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2026-006097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":16,"alternative-id":["10.1136\/spcare-2026-006097"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2026-006097","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}